Results 91 to 100 of about 482,699 (357)
Nature Communications, 2021 A Correction to this paper has been published: https://doi.org/10.1038/s41467-021-22667 ...
John-William Sidhom +3 more
doaj +1 more source
Immunocompetent murine models for the study of glioblastoma immunotherapy. [PDF]
, 2014 Glioblastoma remains a lethal diagnosis with a 5-year survival rate of less than 10%. (NEJM 352:987-96, 2005) Although immunotherapy-based approaches are capable of inducing detectable immune responses against tumor-specific antigens, improvements in ...
Bloch, Orin +9 more
core +2 more sources
Journal of Pharmacy And Bioallied Sciences, 2019 Immunotherapy is one of the newer entities which is promising, at least can be very much helpful as an adjuvant therapy. This newer modality of the treatment in the field of cancer treatment may be the fourth pillar supporting surgery, chemotherapy, and radiotherapy.
Ashford L George +5 more
openaire +4 more sources
Immunotherapy of Brain Cancer [PDF]
Oncology Research and Treatment, 2016 The brain has long been considered an immune-privileged site precluding potent immune responses. Nevertheless, because of the failure of conventional anti-cancer treatments to achieve sustained control of intracranial neoplasms, immunotherapy has been considered as a promising strategy for decades.
Roth, P, Preusser, M, Weller, M
openaire +3 more sources
Molecular Oncology, EarlyView.Pancreatic ductal adenocarcinoma (PDAC) is a disease with very poor prognosis due to therapeutic limitations. We investigated the antitumor effects of cystatin A (CSTA) in PDAC murine models. We are first to confirm that CSTA enhances T helper type 1‐mediated antitumor effects through promotion of dendritic cells and M1 macrophage activity. CSTA can be
Alessandro Nasti +8 more
wiley +1 more source
Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
Journal of Translational Medicine, 2017 Background Nivolumab is an anti-PD1 checkpoint inhibitor active in patients with advanced melanoma and as adjuvant therapy in high-risk metastatic melanoma patients.
Silvana Morello +8 more
doaj +1 more source
Nature Communications, 2021 There is an urgent need to discover blood-based biomarkers to predict response to immune checkpoint inhibitors (ICI). Here the authors show that effective ICI therapy correlates with increased frequency of circulating CX3CR1+CD8+ T cells in preclinical ...
Takayoshi Yamauchi +15 more
doaj +1 more source
Biological therapy in the treatment of melanoma [PDF]
, 2018 Melanoma is one of the most aggressive tumors and its incidence is on the rise. The low rates of survival in metastatic melanoma has led to the development of new drugs for this type of patient, such as biological therapy which has shown remarkable ...
Benea, Vasile +8 more
core +3 more sources
Immunotherapy of Colorectal Cancer [PDF]
Oncology Research and Treatment, 2016 It is known that the immune response, reflected by high T cell infiltrates in primary tumors and metastases, influences the clinical course of colorectal cancer (CRC). Therefore, immunotherapy concepts have been adapted from other tumor entities, which typically rely on the activation of T cells in the tumor microenvironment (e.g.
Jäger, Dirk +5 more
openaire +4 more sources
Molecular Oncology, EarlyView.Prostate cancer is a leading malignancy with significant clinical heterogeneity in men. An 11‐gene signature derived from dysregulated epithelial cell markers effectively predicted biochemical recurrence‐free survival in patients who underwent radical surgery or radiotherapy.
Zhuofan Mou, Lorna W. Harries
wiley +1 more source